Low incidence of venous thromboembolism in Asian myeloma Patients Treated with thalidomide plus dexamethasone

Asia-Pacific Journal of Oncology and Hematology

Volumn 2, Issue 1, 2010, Pages 41-47

  Shyu, Victor Bonfl Hatifl ^a   Wang, Po Nan ^a   Chu, Pao Hsien ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Asia; Multiple myeloma; Thalidomide with dexamethasone therapy; Venous thromboembolic event

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CENTRAL VENOUS CATHETERIZATION; COMORBIDITY; DEHYDRATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; FAMILY HISTORY; HUMAN; INFECTION; LOW DRUG DOSE; MORBIDITY; MULTIPLE MYELOMA; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 80052079413     PISSN: 17596637     EISSN: 17596645     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968-3977.
2. Cavo M, Zagmani E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematolocjtca. 2004;89:826-831.
3. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;126:715-721.
4. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidome in refractory multiple myeloma. N Enfll J Med. 1999;341:1565-1571.
5. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
6. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R, Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
7. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2005;132:584-593.
8. Cavo M, Zagmani E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
9. Richardson P, Schlossman R, Weller E. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
10. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol. 2002;13:1116-1119.
11. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768-771.
12. Dimopoulos M, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991-995.
13. Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004;83:588-591.
14. Rajkumar SV,Blood E, Vesole D, Fonseca R, Greipp PR, Phase in clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006524:431-436.
15. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Blood Coacjul Fibrinolysis Cell Haemost. 2005;93:198-305.
16. Chew H, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-464.
17. Rees D, Cox M, Clegg J. World distribution of factor V Leiden. Lancet. I995;346:1133-1134
18. Rosendaal F, Doggen C, Zivelin A, Arruda V, Aiach M, Siscovick D. Geographic distribution of the 20210 G to A prothrombin variant. Thromlj Haemost. 1998;79:706-708.
19. Murakami H, Shimizu K, Sawamura M, et al. Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. IntJ Hematol. 2009;89:636-641.
20. Hattori Y, Okamoto S-i, Shimada N, et al. Single-institute phase 2 study of thalidomide treatment for refractroy or relapsed multiple myeloma: prognostic factors and unique toxicity profile. Cancer Sci. 2008:99:1243-1250.
21. Kamikawa R, Ikawa K, Morikawa N, Asaoku H, Iwato K, Sasaki A. The pharmokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. Biol Pharmaceut Bull. 2006;29:2331-2334.
22. Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol. 2002;13: 1636-1640.
23. Chiou T-J, Wang T-H, Chao T-Y, et al. Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest. 2007;25:140-147.
24. Huang S-Y, Tang J-L, Yao M, et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann Hematol. 2003;82:558-564.
25. Sharma A, Raina V, Uppal G, Kumar R, Grover J. Long term use of thalidomide: safe and effective. Indian J Cancer. 2007;44:108-110.
26. Okikawa Y, Takimoto Y, Noda M, et al. Single-agent thalidomide for advanced and refractory multiple myeloma (abstract in Japanese). Rinsho Ketsueki. 2003;44:368-374.
27. Murakami H, Handa H, Abe M, et al. Low-dose thalidomide and low-dose dexamethasone therapy in refractory multiple myeloma. Eur J Haematol. 2007;79:234-239.
28. Kinoshita T, Ohno T, Yuge M, et al. Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma. Ann Oncol. 2005;16:V2o6(abstr no. 579).
29. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematolocjtca. 2001;86:399-403.
30. Yuan Z-G, Hou J, Wnag D-X, Fu W-J, Chen Y-B, Xi H. Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma (in Chinese). Chinese J Cancer. 2007;26:1369-1372.
31. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171-2177.
32. Jimenez-Zepeda VH, Dominguez-Martinez VJ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol. 2006 77: 239-244.
33. Koh Y, Bang S-M, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol. 2009 Aug 25 [Epub ahead of print].
34. Qi P-J, Wang Y-F, Xu Y, et al. The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients. Chinese J Hematol. 2008;29:226-233.
35. Jeng W-J, Kuo M-C, Shih L-Y, Chu P-H. Pulmonary embolism in a patient with multiple myeloma receving thalidomide-dexamethasone therapy. Int J Hematol. 2008;87:542.
36. Miyazawa Y, Irisawa H, Uchiumi H, et al. Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone (abstract, csae report). Rinsho Ketsueki. 2006;47:656-660.
37. Leung V, Leung V, Lui W, Chan T, Wong R, Cheng G. Incidence of deep venous thrombosis in hospitalized Chinese medical patients is similar to that in western populations. Thromb Res. 2006;118:763-764.
38. Leizorovicz A, Turpie AGG, Cohen AT, Wong L, Yoo MC, Dans A. Epidemiology of venous thromboembolism in Asian patients undergoing major orthpedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost. 2005;3:28-34.
39. Heng JN, Lai HL. Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution. Thromb Haemost. 2009:101(6): 1095-1099.
40. Sakon M, Maehara Y, Yoshikawa H, Akaza H. Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost. 2006 4: 581-586.
41. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Reu Anticancer Ther. 2007;7:307-315.
42. Zonder JA. Thrombotic complications of myeloma therapy. Hematology. 2006;1:348-355.
43. Zangari M, Fariba S, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003; 29:276-281.
44. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008;112:4924-4934.
45. Palumbo A, Rajkumar SV, Dimopoulos M, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.
46. Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT. Incidence and prophylaxis of venous thromboembolic events in mutiple myeloma patients receiving immunomodulatory therapy. Thromb Res. 2009:123: 679-686.
47. Klein U, Kosely F, Hillengai SJ, et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in replased multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol. 2009;88:67-71.
48. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematoloflico. 2001;86:399-403.
49. Zemanova M, Scudla V, Adam Z, et al. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Neoplasma. 2008; 55(4):345-349.
50. Knight R, Delap RJ, Zeldis JB, Rajkumar SV,Blood. Lenalidomide and venous thrombosis in multiple myeloma. N Emjl J Med. 2006;534:2079-2080.
51. Gardyn J. Thalidomide with continuous low-dose dexamethasone for multiple myeloma. J Clin Oncol. 2005;23:1323.
52. Myers B, Grimley C, Dolan G. Thalidomide and low-dose dexamethasone in myeloma treatment. Br J Haematol. 2001;114(1):245.
53. Scarvelis D, Wells P. Diagnosis and treatment of deep-vein thrombosis. Can Med Assoc J. 2006;175:1087-1092.
54. Wells P, Anderson D, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416-420.
55. Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007:25: 5490-5505.
56. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Enfll J Med. 2003;349:146-153.
57. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. Chest. 2008; 133:454S-545S.